Inhalant Use Disorder

Clinical picture

• Intoxication begins within seconds and lasts 15 to 45 minutes, prompting repeated dosing across hours to sustain the effect.
• Glue sniffer's rash around the mouth and nose, chemical odor on breath and clothing, and paint or solvent staining of the hands are visible clues.
• The picture resembles alcohol intoxication with slurred speech, ataxia, nystagmus, and euphoria, but clears far more quickly afterward.
• Products are cheap and legal: toluene-based glues, spray paint, butane refills, computer duster, correction fluid, and nitrous oxide chargers.
• Use concentrates in younger adolescents and in socioeconomically marginalized or remote communities, and usually occurs in group settings.
• Chronic use brings cognitive dulling, cerebellar ataxia, peripheral neuropathy, and school failure that can persist long after abstinence.

Criteria snapshot

• Requires at least 2 of 11 problematic use indicators within 12 months, applied specifically to a hydrocarbon-based inhalant substance.
• Withdrawal is not part of the inhalant criterion set, since no reliable inhalant withdrawal syndrome has been established.
• Nitrous oxide and the volatile nitrites are coded under other or unknown substance use disorder rather than as inhalant use disorder.
• Severity is graded mild 2-3, moderate 4-5, and severe 6 or more, with remission specifiers and a controlled environment specifier.
• The specific inhalant should be named when known, since toxicity differs sharply between toluene, butane, and halogenated solvents.

Neurobiology

• Volatile solvents are highly lipid-soluble and reach the CNS within seconds, potentiating GABA-A and glycine receptors while blocking NMDA.
• Toluene increases mesolimbic dopamine firing in the ventral tegmental area, producing reinforcement broadly similar to that of alcohol.
• Sudden sniffing death arises from myocardial sensitization to catecholamines, causing fatal arrhythmia when a startled user exerts or is chased.
• Chronic toluene exposure produces white matter demyelination with diffuse leukoencephalopathy, cerebellar atrophy, and corpus callosum thinning.
• Systemic toxicity includes distal renal tubular acidosis, hepatotoxicity, benzene-related aplastic anemia, and nitrite-induced methemoglobinemia.
• Nitrous oxide inactivates vitamin B12, producing subacute combined degeneration with dorsal column signs and megaloblastic changes.

Psychology

• Accessibility and cost drive initiation, since inhalants are often the first intoxicant available to children too young to obtain alcohol.
• Peer modeling within group sniffing sessions supplies both social reinforcement and direct instruction in technique and product selection.
• Escape from abuse, neglect, hunger, and community trauma is a dominant motive, making the behavior powerfully negatively reinforced.
• Users routinely underestimate lethality because the products are ordinary legal household items rather than recognized street drugs.
• Externalizing traits, conduct problems, and early school disengagement predict both initiation and progression to other substances.

Differential & comorbidity

• Differentiate from alcohol intoxication by the chemical odor, the perioral rash, and the far shorter duration of measurable impairment.
• Exclude head injury, hypoglycemia, a postictal state, and CNS infection in any adolescent presenting with acute confusion and ataxia.
• Comorbidity is very high: conduct disorder, ADHD, depression, PTSD, and later alcohol, cannabis, and opioid use disorders.
• Suicide attempts and antisocial behavior are markedly elevated in adolescent inhalant users compared with other adolescent substance users.
• Check a metabolic panel for anion gap acidosis and hypokalemia, plus CBC, LFTs, creatinine, and B12 when nitrous oxide is involved.

Pharmacologic treatment

• No pharmacotherapy is approved or established; treatment is psychosocial, with medication reserved for comorbid psychiatric conditions.
• Acute intoxication requires cardiac monitoring and a deliberately calm approach, since catecholamine surges can precipitate fatal arrhythmia.
• Avoid epinephrine in solvent-related arrhythmia where alternatives exist; beta blockade has been used for the sensitized myocardium.
• Treat nitrous oxide neuropathy with high-dose vitamin B12 replacement, following methylmalonic acid and homocysteine to gauge response.
• Treat comorbid ADHD, depression, and anxiety, since untreated symptoms sustain use and undermine treatment engagement.

Psychotherapy

• CBT and motivational enhancement therapy adapted for adolescents form the core, delivered with cognitively simplified language.
• Multisystemic therapy and multidimensional family therapy address the family and community context that sustains the use.
• Contingency management with tangible reinforcers improves attendance and abstinence across adolescent substance treatment programs.
• Cognitive impairment often requires slower pacing, repetition, visual aids, and shorter sessions than standard manuals assume.
• School reintegration and vocational engagement supply competing reinforcement in communities with few alternative activities.

Adjunct options

• Community-level supply restriction, product reformulation, and retailer education reduce access more effectively than individual counseling.
• Neuropsychological testing documents deficits and guides realistic educational and vocational planning once abstinence is established.
• Assess housing, food security, child protection, and caregiver substance use, since inhalant use signals broader family crisis.
• Residential treatment is often necessary, as outpatient care rarely separates the adolescent from the using peer group.
• Involve child protective services when use occurs in a child under 12 or when supervision failures are clearly evident.

Clinical pearls

• Sudden sniffing death can occur on a first use; there is no safe exposure level.
• Nitrous oxide inactivates B12; look for subacute combined degeneration.
• Perioral rash plus solvent odor in a young teen is inhalant use until disproven.